vidaza
bristol-myers squibb pharma eeig - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine accord
accord healthcare s.l.u. - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - azacitidine accord ενδείκνυται για τη θεραπεία ενήλικων ασθενών που δεν είναι επιλέξιμες για την αιμοποιητική μεταμόσχευση βλαστικών κυττάρων (hsct) με:- ενδιάμεσου-2 και υψηλού κινδύνου μυελοδυσπλαστικά σύνδρομα (ΜΔΣ), σύμφωνα με το Διεθνές Σύστημα Προγνωστικής Βαθμολόγησης (ipss),- χρόνια myelomonocytic λευχαιμία (chronic myelomonocytic leukaemia, cmml) με 10-29 % βλαστών μυελού χωρίς μυελοϋπερπλαστική διαταραχή,- οξεία μυελογενή λευχαιμία (aml) με 20-30 % βλάστες και πολυ-καταγωγή δυσπλασία, σύμφωνα με την Παγκόσμια Οργάνωση Υγείας (ΠΟΥ) ταξινόμηση,- ΟΜΛ με >30% βλαστών μυελού, σύμφωνα με την ταξινόμηση ΠΟΥ.
probenecid biokanol 500mg tablets
biokanol pharma gmbh (0000003726) kehler strasse 7, rastatt, 76437 - probenecid - tablets - 500mg - probenecid (0000057669) 500mg - probenecid
oramorph 10mg/5ml oral solution
glenwood gmbh (0000011526) arabellastrasse 17, bogenhausen, munich, 81925 - morphine sulfate - oral solution - 10mg/5ml - morphine sulfate (0000064313) 10mg
difene dual release 100mg modified-release capsule, hard
medilink pharmaceuticals ltd (0000003162) 30 armenias, strovolos, 1640, 26576 - diclofenac sodium - modified-release capsule, hard - 100mg - diclofenac sodium (0015307796) 100mg - diclofenac
difene dual release 75mg capsule,hard
medilink pharmaceuticals ltd (0000003162) 30 armenias, strovolos, 1640, 26576 - diclofenac sodium - capsule,hard - 75mg - diclofenac sodium (0015307796) 75mg - diclofenac
zenalb 20 20% solution for infusion
bpl bioproducts laboratory gmbh (0000011488) dornhofstrasse 34, neu-isenburg, 63263 - albumin human - solution for infusion - 20% - albumin human (8000020282) 200g - albumin
thiopental rotexmedica
rotexmedica gmbh - ΘΕΙΟΠΕΝΤΆΛΗ ΤΟ ΝΆΤΡΙΟ ΚΑΙ ΤΟ ΑΝΘΡΑΚΙΚΌ ΝΆΤΡΙΟ - powder for injection - 1000mg/vial - 8000004465 - thiopental sodium and sodium carbonate - 1000 mg - thiopental